Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Dr. Ivan de Kouchkovsky explains how radioligand therapy delivers targeted radiation to prostate cancer cells using a radioactive isotope attached to a molecule that binds to PSMA, a protein commonly expressed in these tumors. He reviews key clinical trials showing how the therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer, both after and before chemotherapy. The FDA now approves this approach for patients who have progressed on hormone therapy, even if they haven’t yet received chemotherapy. De Kouchkovsky also highlights efforts to enhance effectiveness by combining therapies, increasing radiation dose, and targeting resistant or PSMA-negative cells. Diagnostic imaging plays a critical role in selecting patients most likely to benefit from treatment. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40810]

You can listen to Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) online on Radio and Podcast. Open the player on this page to stream the available audio.

Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an episode from Winning the War on Cancer (Audio) by UCTV.

This episode is 00:11:03 long.

This episode was published on Aug 4, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Winning the War on Cancer (Audio) when more episodes are available from the podcast feed.